This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study has been withdrawn prior to enrollment.
(No resources available)
Information provided by:
Imperial College London Identifier:
First received: September 8, 2005
Last updated: June 3, 2015
Last verified: August 2008
The primary aim of this study is to investigate the effects of inhaled lipopolysaccharide endotoxin (LPS) on bronchial and alveolar exhaled nitric oxide (NO) and NO metabolites and other inflammatory markers and mediators in exhaled breath condensate, induced sputum, nasal lavage and mouthwash fluid in healthy non-smokers and current smokers, including patients with chronic obstructive pulmonary disease (COPD).

Condition Intervention
Chronic Obstructive Pulmonary Disease Procedure: Inhalation of LPS Procedure: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: Effect of Endotoxin on Inflammatory Markers in Exhaled Breath, Sputum, Saliva and Nasal Lavage in Healthy Non-Smokers and Current Smokers Including Patients With COPD

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • sputum induced

Enrollment: 0
Study Start Date: June 2003
Arms Assigned Interventions
Experimental: 1
Inhalation of LPS
Procedure: Inhalation of LPS
Placebo Comparator: 2
Procedure: Placebo


Ages Eligible for Study:   21 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy non-smokers: normal spirometry (forced expiratory volume in 1 second [FEV1] more than or equal to 90% predicted) and normal exhaled NO (between 8 and 24 ppb; flow 50 ml/s)
  • 0: At risk (current or ex-smokers): normal spirometry, with or without chronic symptoms (cough, sputum production)
  • I-II: Mild-moderate COPD

    • FEV1 reversibility of < 15% after inhaled beta2-agonists
    • FEV1/forced vital capacity (FVC) < 70% predicted
    • FEV1 between greater than or equal to 50% and less than 80%
    • With or without chronic symptoms (cough, sputum production)
  • Able to comprehend and grant a written informed consent

Exclusion Criteria:

  • Concomitant use or pre-treatment within the last 4 weeks with oral steroids
  • Respiratory infection within 4 weeks prior to entry into the trial
  • Females who are pregnant or lactating
  • History of current or past drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00159289

United Kingdom
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY
Sponsors and Collaborators
Imperial College London
Principal Investigator: Sergei A Kharitonov, MD, PhD Imperial College London
  More Information Identifier: NCT00159289     History of Changes
Other Study ID Numbers: 2002AT032B
Study First Received: September 8, 2005
Last Updated: June 3, 2015

Keywords provided by Imperial College London:
Mild to moderate Chronic Obstructive Pulmonary Disease (COPD)
Volunteers (healthy non-smokers)
Volunteers (current or ex-smokers)

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on September 21, 2017